Price (delayed)
$15.005
Market cap
$930.73M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.79
Enterprise value
$686.44M
gh research is a privately-held clinical-stage biopharmaceutical company developing novel therapies for the management of mental illness.
There are no recent dividends present for GHRS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.